Notwithstanding positive clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial opposition from PBMs. These companies are often creating limitations to access, including significant cost restrictions and PA that limit consumer availability. Industry indicate that these … Read More